
Opinion|Videos|March 4, 2025
Treatment Options in mCRC: A Clinical Overview
Experts provide an overview of third-line treatment options for metastatic colorectal cancer (mCRC) in patients with disease progression through all available regimens, focusing on fruquintinib, regorafenib, and trifluridine + tipiracil ± bevacizumab.
Advertisement
Episodes in this series

Now Playing
Video content above is prompted by the following:
- Provide an overview of the third-line treatment options for mCRC for patients with disease that has progressed through all available regimens.
- Fruquintinib
- Regorafenib
- Trifluridine + tipiracil ± bevacizumab
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Timely Outpatient Follow-Up Reduces Hospital Readmissions
2
Changing Tumor Classifications May Explain Rise in Early-Onset CRC
3
Medicaid Work Requirements Set to Leave Millions Without Insurance
4
Remote Physiological Monitoring Improves Patient Access, Care, and Revenue
5














































